12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes

12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes

Non-Hodgkin Lymphomas (NHL) represent a heterogeneous group of lymphoproliferative malignancies arising predominantly from B-lymphocytes (~85–90%), T-lymphocytes (~10–15%), or natural killer (NK) cells. Systemic therapeutic management is dictated by histologic grade (aggressive vs. indolent), cell-of-origin (COO), cytogenetic translocations (e.g., MYC, BCL2, BCL6, CCND1), the International Prognostic Index (IPI), and patient-specific fitness.

Board-certified oncology pharmacists must navigate complex molecular diagnostics, calculate specialized dose-adjusted protocols (e.g., DA-EPOCH-R), intercept severe drug interactions with targeted kinase inhibitors, manage bispecific T-cell engager step-up dosing to prevent cytokine release syndrome (CRS), and institute comprehensive antimicrobial prophylaxis regimens.

---

1. Diffuse Large B-Cell Lymphoma (DLBCL) & Aggressive B-Cell Lymphomas

DLBCL is the most common lymphoid malignancy in adults, accounting for ~30–35% of newly diagnosed NHL cases.

Cell of Origin & Molecular Classification

• Cell of Origin (COO): Gene expression profiling segregates DLBCL into Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC / Non-GCB) subtypes. In clinical practice, the Hans Immunohistochemistry Algorithm serves as the validated surrogate:

+---------------------------------------------------------------------------------------------------+
|                             HANS IMMUNOHISTOCHEMICAL ALGORITHM FOR DLBCL                          |
|                                                                                                   |
|                                          [CD10 Expression]                                        |
|                                                  |                                                |
|                         +------------------------+------------------------+                       |
|                         | (Positive >=30%)                                | (Negative <30%)       |
|                         v                                                 v                       |
|                   [GCB SUBTYPE]                                    [BCL6 Expression]              |
|                                                                           |                       |
|                                                  +------------------------+-------------------+   |
|                                                  | (Negative <30%)            (Positive >=30%)|   |
|                                                  v                                            v   |
|                                            [NON-GCB / ABC]                            [MUM1 Expr] |
|                                                                                           |       |
|                                                                   +-----------------------+---+   |
|                                                                   | (<30%)            (>=30%) |   |
|                                                                   v                           v   |
|                                                             [GCB SUBTYPE]               [NON-GCB] |
+---------------------------------------------------------------------------------------------------+

• High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements ("Double-Hit" / "Triple-Hit" Lymphoma): Defined by cytogenetic translocations detected via fluorescence in situ hybridization (FISH). These carry an exceptionally poor prognosis with standard R-CHOP (2-year PFS <40%) and mandate intensive frontline therapy with Dose-Adjusted EPOCH-R.
• Double-Expressor Lymphoma (DEL): Defined by protein overexpression on IHC (MYC >=40% and BCL2 >=50%) without underlying gene rearrangements on FISH. DEL is treated with standard frontline chemoimmunotherapy (Pola-R-CHP or R-CHOP).

International Prognostic Index (IPI) Scoring

One point is assigned for each risk factor (APLES):

• Age > 60 years
• Performance status (ECOG >= 2)
• LDH > upper limit of normal
• Extranodal sites >= 2
• Stage III or IV
• Risk Strata: Low (0–1), Low-Intermediate (2), High-Intermediate (3), High (4–5).

Frontline Systemic Therapy Protocols

+---------------------------------------------------------------------------------------------------+
|                    FRONTLINE DLBCL REGIMEN SELECTION: Pola-R-CHP vs R-CHOP                        |
|                                                                                                   |
|   [POLARIX TRIAL: Pola-R-CHP] (Tilly et al. NEJM 2022)                                            |
|   - Target: IPI 2 to 5 (Intermediate-to-High Risk DLBCL)                                          |
|   - Polatuzumab vedotin: 1.8 mg/kg IV Day 1 (Anti-CD79b ADC with MMAE payload)                    |
|   - Rituximab: 375 mg/m2 IV Day 1                                                                 |
|   - Cyclophosphamide: 750 mg/m2 IV Day 1                                                          |
|   - Doxorubicin: 50 mg/m2 IV Day 1                                                                |
|   - Prednisone: 100 mg PO daily Days 1 to 5                                                       |
|   - (VINCRISTINE IS REMOVED AND REPLACED BY POLATUZUMAB VEDOTIN)                                  |
|   - Cycle: Every 21 days x 6 cycles (plus 2 additional doses of single-agent Rituximab)           |
|   - Efficacy: 2-year PFS **76.7% vs. 70.2%** (HR 0.73, p = 0.02); OS similar at 2 years           |
|   - Subgroup Benefit: Most pronounced in ABC/Non-GCB subtype and IPI 3-5                          |
|                                                                                                   |
|   [STANDARD R-CHOP-21]                                                                            |
|   - Target: IPI 0 to 1 (Low Risk) or select GCB subtype                                           |
|   - Rituximab 375 mg/m2 + Cyclophosphamide 750 mg/m2 + Doxorubicin 50 mg/m2 +                     |
|     Vincristine 1.4 mg/m2 (CAPPED AT 2.0 mg) Day 1 + Prednisone 100 mg PO D1-5 Q21D x 6 cycles    |
+---------------------------------------------------------------------------------------------------+

Dose-Adjusted EPOCH-R (DA-EPOCH-R) Pharmacist Dosing Algorithm

Used in Double-Hit/Triple-Hit HGBL, Primary Mediastinal B-Cell Lymphoma (PMBCL), and Burkitt Lymphoma. Administered as a 96-hour continuous IV infusion:

• Etoposide: 50 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 200 mg/m2)
• Doxorubicin: 10 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 40 mg/m2)
• Vincristine: 0.4 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 1.6 mg/m2—NO 2 mg DOSE CAP!)
• Cyclophosphamide: 750 mg/m2 IV on Day 5
• Prednisone: 60 mg/m2 PO BID on Days 1–5
• Rituximab: 375 mg/m2 IV on Day 1
• Pharmacist Dose Titration Rules: Adjust Etoposide, Doxorubicin, and Cyclophosphamide for subsequent cycles based on the nadir ANC and platelet count from twice-weekly CBCs:
  • If nadir ANC >= 500/mcL on all measurements: Increase doses of Etoposide, Doxorubicin, and Cyclophosphamide by 20%.
  • If nadir ANC < 500/mcL on 1 or 2 measurements: Maintain same dose.
  • If nadir ANC < 500/mcL for >= 3 measurements OR nadir Platelets < 25,000/mcL: Decrease doses by 20%.

Central Nervous System (CNS) Prophylaxis in DLBCL

Patients with high risk of CNS relapse (CNS-IPI score >=4, involvement of kidney, adrenal glands, testes, bone marrow, or Double-Hit status) mandate CNS prophylaxis:

• Preferred: High-Dose Methotrexate (HD-MTX >=3.0–3.5 g/m2 IV) with aggressive hyperhydration (urine output >100 mL/h), urinary alkalinization (urine pH >=7.5 with sodium bicarbonate), and leucovorin rescue, administered intercalated on Day 15 of chemoimmunotherapy cycles or after completion of systemic therapy.
• Alternative: Intrathecal methotrexate (12 mg) and/or cytarabine (50 mg).

---

2. Relapsed & Refractory DLBCL: CAR T-Cell & Bispecific Therapeutics

+---------------------------------------------------------------------------------------------------+
|                     SECOND-LINE & LATER RELAPSED / REFRACTORY DLBCL ALGORITHM                     |
|                                                                                                   |
|   PRIMARY REFRACTORY OR EARLY RELAPSE (<12 MONTHS FROM COMPLETION OF CHEMOIMMUNOTHERAPY)          |
|                                   |                                                               |
|                                   v                                                               |
|   [AUTOLOGOUS ANTI-CD19 CAR T-CELL THERAPY] (Category 1 Preferred Standard)                       |
|   - **Axicabtagene ciloleucel (Axi-cel)** (ZUMA-7: 2-yr EFS 40.5% vs 16.3%, OS HR 0.73) OR        |
|   - **Lisocabtagene maraleucel (Liso-cel)** (TRANSFORM: EFS 10.1 vs 2.3 mo, HR 0.35)              |
|   - SUPERIOR TO PLATINUM SALVAGE (R-ICE/R-DHAP) + AUTO-HCT!                                       |
|                                                                                                   |
|   LATE RELAPSE (>=12 MONTHS) & TRANSPLANT-ELIGIBLE                                                |
|                                   |                                                               |
|                                   v                                                               |
|   [PLATINUM SALVAGE CHEMOTHERAPY] -> If Chemoresponsive (CMR/PMR) -> [HIGH-DOSE CHEMO + AUTO-HCT]|
|   - Regimens: R-ICE, R-DHAP, or R-GDP                                                             |
|                                                                                                   |
|   THIRD-LINE OR POST-CAR T / TRANSPLANT-INELIGIBLE RELAPSE                                        |
|                                   |                                                               |
|         +-------------------------+-------------------------+                                     |
|         |                                                   |                                     |
|         v                                                   v                                     |
|   [CD20 x CD3 BISPECIFIC ANTIBODIES]                 [ANTIBODY-DRUG CONJUGATES / TARGETED]        |
|   - **Epcoritamab** (EPCORE NHL-1; Subcutaneous;     - **Loncastuximab tesirine** (LOTIS-2;       |
|     Step-up dosing D1, D8, D15)                        Anti-CD19 ADC with PBD alkylator payload)  |
|   - **Glofitamab** (NP30179; IV; 2:1 CD20:CD3;       - **Tafasitamab + Lenalidomide** (L-MIND;    |
|     Obinutuzumab pretreatment, 12 fixed cycles)        Anti-CD19 mAb + immunomodulatory agent)    |
+---------------------------------------------------------------------------------------------------+

CD20 x CD3 Bispecific T-Cell Engagers (BsAbs) in DLBCL

---

3. Indolent B-Cell Lymphomas: Follicular & Marginal Zone Lymphomas

Follicular Lymphoma (FL)

Follicular lymphoma is the second most common NHL (~20–25%), characterized by the pathognomonic chromosomal translocation t(14;18)(q32;q21), which places the BCL2 proto-oncogene under the control of the immunoglobulin heavy chain (IGH) promoter, causing constitutive BCL-2 overexpression and inhibition of apoptosis.

• Histologic Grading: Grade 1 (0–5 centroblasts/HPF), Grade 2 (6–15 centroblasts/HPF), Grade 3A (>15 centroblasts with centrocytes present), Grade 3B (sheets of centroblasts without centrocytes). Grade 3B is treated aggressively as DLBCL! (R-CHOP / Pola-R-CHP).
• Indications for Treatment (GELF Criteria):
  • Involvement of >=3 nodal sites, each with diameter >=3 cm
  • Any single nodal or extranodal mass >=7 cm
  • Symptomatic splenomegaly
  • Organ compression / risk of vital organ compromise
  • Ascites or pleural effusion
  • Cytopenias (ANC <1,000/mcL or Platelets <100,000/mcL)
  • Systemic B symptoms
  • Asymptomatic low tumor burden patients are managed with Watchful Waiting (observation).

+---------------------------------------------------------------------------------------------------+
|                    FRONTLINE HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA MATRIX                         |
|                                                                                                   |
|   [BENDAMUSTINE + OBINUTUZUMAB (G-Benda) or RITUXIMAB (BR)]                                       |
|   - **Bendamustine:** 90 mg/m2 IV Days 1 and 2 Q28D x 6 cycles                                    |
|   - **Obinutuzumab:** 1,000 mg IV C1D1, D8, D15; then Day 1 of Cycles 2-6 (GALLIUM trial) OR       |
|   - **Rituximab:** 375 mg/m2 IV Day 1 Q28D x 6 cycles (StiL / BRIGHT trials)                      |
|   - Efficacy: G-chemo improves PFS over R-chemo (7-yr PFS 63% vs 55%; HR 0.77, p=0.006)           |
|   - Maintenance: Obinutuzumab or Rituximab 1,000 mg/375 mg/m2 Q2M x 2 years                       |
|   - PHARMACIST MANDATE: **Mandatory PJP prophylaxis (TMP-SMX) and VZV/HSV prophylaxis             |
|     (Acyclovir/Valacyclovir)** throughout therapy and for >=6-12 months post-bendamustine due     |
|     to profound, prolonged CD4+ T-cell depletion (CD4 nadir often <200/mcL)!                      |
|                                                                                                   |
|   [R-CHOP / G-CHOP] or [R-CVP / G-CVP]                                                            |
|   - Preferred when high risk of histologic transformation to DLBCL is suspected                   |
|   - Followed by 2 years of maintenance CD20 antibody in responders                                |
|                                                                                                   |
|   [R-SQUARED (R2) REGIMEN: RELEVANCE & AUGMENT TRIALS]                                            |
|   - **Lenalidomide:** 20 mg PO daily Days 1 to 21 Q28D x 6 to 12 cycles                           |
|   - **Rituximab:** 375 mg/m2 IV weekly x 4 doses (Cycle 1), then Day 1 of Cycles 2 to 5          |
|   - Non-cytotoxic chemo-free option; mandatory antithrombotic prophylaxis (Aspirin 81 mg daily)   |
+---------------------------------------------------------------------------------------------------+

Relapsed/Refractory Follicular Lymphoma Targeted Agents

• Mosunetuzumab: Full CD20 x CD3 bispecific antibody with step-up dosing (Day 1: 1 mg, Day 8: 2 mg, Day 15: 60 mg, Cycle 2 Day 1: 60 mg, Cycle 3+ Day 1: 30 mg Q21D for 8–17 cycles). Established 80% ORR and 60% CR rate in heavily pretreated FL.
• Zanubrutinib + Obinutuzumab: ROSEWOOD trial demonstrated PFS superiority over obinutuzumab monotherapy in relapsed/refractory FL.
• Tazemetostat: Oral EZH2 methyltransferase inhibitor (800 mg PO BID) indicated for relapsed/refractory FL harboring EZH2 gain-of-function mutations (or wild-type with no alternative therapies).

---

4. Mantle Cell Lymphoma (MCL)

MCL represents ~5–7% of NHL cases, characterized by the hallmark translocation t(11;14)(q13;q32), which fuses the CCND1 gene to the IGH enhancer, resulting in overexpression of Cyclin D1 and cell cycle progression from G1 to S phase. It is universally positive for SOX11 and CD5+ / CD19+ / CD20+ / CD23-.

+---------------------------------------------------------------------------------------------------+
|                         MANTLE CELL LYMPHOMA (MCL) TREATMENT PARADIGM                             |
|                                                                                                   |
|   [YOUNG / FIT / TRANSPLANT-ELIGIBLE MCL]                                                         |
|   - Induction: High-dose Cytarabine-containing chemoimmunotherapy (MANDATORY):                   |
|     * Alternating R-CHOP / R-DHAP (LyMa trial) OR Nordic Regimen (Maxi-CHOP / High-dose Ara-C)    |
|     * HyperCVAD + Rituximab alternating with HD-MTX/Cytarabine                                    |
|   - Consolidation: High-Dose Chemotherapy (BEAM) + **Autologous Stem Cell Transplantation**      |
|   - Maintenance: **Maintenance Rituximab 375 mg/m2 IV every 2 months for 3 YEARS**               |
|     * LyMa Trial (Hermine et al. NEJM 2017): 4-yr EFS 79% vs 61%; **4-yr OS 89% vs 80% (HR 0.50)**|
|                                                                                                   |
|   [ELDERLY / TRANSPLANT-INELIGIBLE MCL]                                                           |
|   - Induction: Bendamustine + Rituximab (BR) x 6 cycles OR VR-CAP (Bortezomib substituted for VCR)|
|   - Maintenance: Maintenance Rituximab every 2 months for 2 years (or until progression)          |
|                                                                                                   |
|   [TP53-MUTATED MCL (10-15% of cases)]                                                            |
|   - Chemoresistant phenotype with poor median OS (<2-3 years) with traditional chemo-HCT          |
|   - Prioritize BTK inhibitor + Venetoclax clinical trials or frontline BTK inhibitor combinations |
|                                                                                                   |
|   [RELAPSED / REFRACTORY MCL THERAPEUTICS]                                                        |
|   - Second-Generation Covalent BTK Inhibitors (Preferred over Ibrutinib due to lower AF/bleeding):|
|     * **Acalabrutinib:** 100 mg PO BID (Avoid PPIs; take 2h before H2RAs/antacids)                |
|     * **Zanubrutinib:** 160 mg PO BID or 320 mg PO daily (No gastric pH interaction)              |
|   - Non-Covalent (Reversible) BTK Inhibitor:                                                      |
|     * **Pirtobrutinib:** 200 mg PO daily (BRUIN trial; retains potency against C481S mutations!)   |
|   - CAR T-Cell Therapy: **Brexucabtagene autoleucel (Tecartus)** post-BTK progression (ZUMA-2)    |
+---------------------------------------------------------------------------------------------------+

---

5. T-Cell & Cutaneous Lymphomas

T-cell lymphomas represent aggressive, biologically distinct neoplasms requiring specialized biomarker-directed therapy.

Peripheral T-Cell Lymphoma (PTCL)

• CD30 Expression: Expressed in 100% of Anaplastic Large Cell Lymphoma (ALCL; ALK+ and ALK-) and variable subsets (15–50%) of PTCL-Not Otherwise Specified (PTCL-NOS) and Angioimmunoblastic T-Cell Lymphoma (AITL).
• Frontline Standard (ECHELON-2 Trial; Pro et al. Lancet 2019):
  • BV-CHP: Brentuximab vedotin (1.8 mg/kg IV) + Cyclophosphamide (750 mg/m2) + Doxorubicin (50 mg/m2) + Prednisone (100 mg PO D1–5) Q21D x 6 cycles. (Vincristine omitted).
  • Efficacy: Significant PFS and OS improvement over CHOP (5-year OS 70.1% vs. 61.0%, HR 0.72).
  • Consolidate with Autologous HCT in first remission for fit patients with non-ALK+ ALCL, AITL, and PTCL-NOS.
• Relapsed PTCL Agents: Pralatrexate (antifolate; mandatory pre-supplementation with Vitamin B12 1 mg IM Q8–10W and Folic Acid 1 mg PO daily to prevent lethal mucositis and myelosuppression), Romidepsin (HDAC inhibitor; baseline ECG/QTc monitoring), Belinostat.

Cutaneous T-Cell Lymphoma (CTCL: Mycosis Fungoides & Sézary Syndrome)

• Mogamulizumab: Monoclonal antibody targeting CCR4 (chemokine receptor 4) with enhanced ADCC. Phase 3 MAVORIC trial demonstrated superior PFS over vorinostat, with dramatic clearance of the leukemic/blood compartment in Sézary syndrome. Toxicities: dermatologic rash (drug eruption vs disease flare; skin biopsy required), infusion reactions, risk of severe GVHD if subsequently undergoing allogeneic HCT.
• Bexarotene: Oral retinoid X receptor (RXR) selective agonist (300 mg/m2 PO daily with a meal). Signature toxicities requiring proactive pharmacist co-prescription:
  1. Severe Hypertriglyceridemia (>80%): Initiate prophylactic Fenofibrate (avoid gemfibrozil due to CYP2C8 interaction) or omega-3 fatty acids before starting.
  2. Central Hypothyroidism (>90%): Suppresses pituitary TSH secretion; initiate prophylactic Levothyroxine (Synthroid 25–50 mcg daily) and monitor Free T4 (not TSH!).
• Vorinostat: Oral histone deacetylase (HDAC) inhibitor (400 mg PO daily with food). Toxicities: fatigue, severe diarrhea, thromboembolism (DVT/PE in 5%), QTc prolongation.